Atypical (dysplastic) melanocytic nevi are clinically heterogeneous malignant melanoma precursors, for which no topographic analysis of cell kinetic, cell cycle regulators and microsatellite profile is available. We selected low-grade atypical melanocytic nevi (92), high-grade atypical melanocytic nevi (41), melanocytic nevi (18 junctional, 25 compound) and malignant melanomas (16 radial growth phase and 27 vertical growth phase). TP53, CDKN2A, CDKN1A, and CDKN1B microsatellite patterns were topographically studied after microdissection; Ki-67, TP53, CDKN2A, CDKN1A, and CDKN1B expressions and DNA fragmentation by in situ end labeling for apoptosis were topographically scored. Results were statistically analyzed. A decreasing junctional-dermal marker expression gradient was observed, directly correlating with atypical melanocytic nevus grading. High-grade atypical melanocytic nevi revealed coexistent TP53-CDKN2A-CDKN1B microsatellite abnormalities, and significantly higher junctional Ki67-TP53 expression (inversely correlated with CDKN1A-CDKN1B expression and in situ end labeling). Malignant melanomas showed coexistent microsatellite abnormalities (CDKN2A-CDKN1B), no topographic gradient, and significantly decreased expression. Melanocytic nevi and low-grade atypical melanocytic nevi revealed sporadic junctional CDKN2A microsatellite abnormalities and no significant topographic kinetic differences. High-grade atypical melanocytic nevi accumulate junctional TP53-CDKN1A-CDKN1B microsatellite abnormalities, being progression TP53-independent and better assessed in the dermis. Melanocytic nevi and low-grade atypical melanocytic nevi show low incidence of microsatellite abnormalities, and kinetic features that make progression unlikely.
Neoplastic transformation is a multistep process, which in certain locations correlates with progressive morphological changes.
1 Atypical (dysplastic) melanocytic nevi are considered to be the intermediate step in the continuous process from acquired melanocytic nevi to malignant melanoma, [2] [3] [4] which proceeds through radial and vertical growth phases and eventually metastasis. 3 Although atypical melanocytic nevi reveal progressive morphological changes, 5 the grading system is controversial and its prognostic relevance is not fully established.
The evolution of neoplasms occurs as a result of the progressive and convergent selection of cell populations, which is a direct expression of the cell kinetics segregation process by either increased proliferation or abnormally low cell loss, resulting in tissue growth. [6] [7] [8] Selective kinetic advantages contribute to dominant growth [9] [10] [11] [12] and are mainly regulated at the restriction point by TP53, pRB, and cyclin-dependent kinase inhibitors (Figure 1 ), 13 where a maintained G 1 arrest will lead to apoptosis only if pRB is not functional. 1, 14 Genetic lesions within all cells imply a common progenitor contributing that mutation, 9, 15, 16 and it has been found to be associated with loss of heterozygosity of certain loci. 7, 17 The DNA deletions of a given genetic marker should be linked to the loss of tumor suppressor genes, 15, 16 which also contribute to the multistep carcinogenesis process selecting those cells with growth advantages. 9 A monoclonal tumor origin is supported by concordant tumor suppressor gene abnormalities, 7, 17, 18 which have been found to be associated with the loss of heterozygosity of certain loci. The coexistence of several genetic abnormalities and intratumor heterogeneity would be the expression of either tumor cell selection or a simple passive byproduct of genetic instability. 19, 20 However, the association of multiple genetic alterations would become statistically less probable as the number of molecular markers increases and is useful to test clonal expansions in tumors. 7, 18 Although genetic abnormalities are probably asymmetrically acquired, there is a correlation with tumor cell topography in both luminal and solid organs, 1, [19] [20] [21] [22] [23] which has not been assessed in skin melanocytic lesions. Any potential topographic segregation of tumor cells will influence interpretations of the results, supporting a linear model if progressive grading is parallel to intraepithelial-to-invasive topography of tumor cells.
Multistep tumorigenesis is a widely accepted concept that has been examined both morphologically and genetically, most of the times as part of a linear model. The G1-S transition of the cell cycle and cell survival through telomere/telomerase is a point that shows alterations in almost all kinds of tumors and systems, and it is likely to reveal differential patterns during progression of melanocytic lesions. An analysis by topographic compartments would eventually help to explain the diagnostic features and the topographic cell segregation in atypical (dysplastic) melanocytic lesions. The independent analysis of several cell cycle regulators in separate topographic tumor cell compartments from a series of melanocytic lesions with progressive degree of atypia will offer the opportunity to check the validity of the linear progression in atypical melanocytic lesions.
This study investigates the topographic profile of cell kinetics, telomerase, and the G 1 -S cell cycle regulators (Table 1) , based on the immunoexpression and microsatellite analyses of tumor suppressor genes using microdissected tissue samples from atypical melanocytic nevi and the corresponding melanocytic controls. This study aims to study topographic progression and grading in atypical melanocytic nevi.
Materials and methods

Case Selection and Sampling
We retrospectively studied 133 consecutive cases of clinically diagnosed atypical melanocytic nevi (53 junctional and 80 compound) in 121 patients from the Barts and The London Hospitals (London, UK) and University Hospital (Malaga, Spain). All specimens were fixed in 10% buffered formalin, routinely Figure 1 The role of TP53, RB1, and cyclin-dependent kinase inhibitor in regulating the G 1 -S transition, apoptosis, and telomerase expression (both RNA component (TERC) and reverse transcriptase (TERT)).
processed, serially sectioned, and stained with hematoxylin-eosin (H&E). All nevi fulfilled the standard definition of atypical melanocytic nevi, showed both architectural and cytologic atypia, and were evaluated histologically by two independent observers (AB and SJD-C), according to standard criteria. Reproducibility data were not recorded. No case had evidence of scarring, incomplete resection precluding adequate evaluation, or features suggesting congenital onset. The clinical records were reviewed for patient age, nevus location, and familial-personal history of atypical-mole syndrome or malignant melanoma. The grading was evaluated on multiple, H&E-stained, routine sections of the whole lesion. All atypical melanocytic nevi were required to show architectural and cytological atypia (at least one criterion from each group) and were scored according to the number of criteria fulfilled, into low grade, including mild (2-3 criteria) and moderate (4-5 criteria), and high grade or severe (6-7 criteria). The diagnosis of HG-atypical melanocytic nevi required at least one architectural and two cytological variables, with nuclear pleomorphism being an obligatory criterion. 5 Processing artifacts were found to influence the cohesion of cells in nests (from preserved to diminished), this feature being therefore excluded from the final classification. In case of grading disagreement, the lesions were discussed during simultaneous inspection before final categorization.
Conventional melanocytic nevi (18 junctional, 25 compound) and malignant melanomas (16 radialgrowth-phase malignant melanoma and 27 vertical growth phase) were used as benign and malignant controls of melanocytic proliferations. The growth phase of malignant melanoma was defined according to standard criteria. 3 
TSG Microsatellite Analysis
DNA was extracted from the most cellular areas of junctional, superficial, and deep compartments, 17, 20, 23, 24 after microdissecting at least 100 cells (B0.4 mm 2 , PixCell II Laser Capture Microdissection, Arcturus Engineering Inc., Mountain View, CA, USA) from two 20-mm unstained paraffin sections/compartment (Figure 1 ). Appropriate controls (histologically normal epidermis and dermis) and quality assurance (sensitivity, specificity, positive and negative) were run for each test. 7, 18, 25 DNA was extracted using a modified phenolchloroform protocol, precipitated with ice-cold absolute ethanol, and resuspended in 10 ml of TrisHCl buffer, pH 8.4. 26 DNA was then used for polymerase chain reaction (PCR) amplification of the intron microsatellites of tumor suppressor genes (Table 2) . 17, 20 Multiplex PCR was performed using Qiagen s multiplex PCR kit (Qiagen Ltd., West Sussex, UK). Each multiplex PCR reaction included 5 ml Qiagen multiplex PCR master mix, 1 ml of 10 Â primer mix, 2 ml distilled water, and 2 ml genomic DNA. PCR was performed using a PTC225 (MJ Research) thermocycler. The multiplex PCR protocol was performed using Qiagen Multiplex PCR was performed according to the manufacturer's instructions: an initial step at 951C for 15 min to activate HotStarTaq DNA polymerase, followed by a three-step cycling of denaturation at 941C for 30 s, annealing at 571C for 90 s, and extension at 721C for 60 s. This was repeated for 35 cycles. A final extension was performed at 601C for 30 min.
A mixture of 0.5 ml Genscan 400 ROX HD internal size standard (Applied Biosystems, Foster City, CA, USA) and 18.5 ml formamide was added to 1 ml of each PCR product. The final mix was heated for 5 min at 951C to denature double-stranded DNA prior to genotyping. The fluorescent PCR products were subsequently fractionated on a capillary-based laser-activated ABI PRISM s 3700 (Applied Biosystems), and analyzed (size and peak high) using ABI Genotyper 3.7 software (Applied Biosystems).
Interpretation and inclusion criteria in each sample included the following: (a) Allelic imbalance showed evidence of loss of heterozygosity when allele ratios were Z4:1 in any tumor suppressor gene; otherwise retention of heterozygosity was assigned. 7, 18, 20, 24, 27, 28 This ratio represents 80% of clonal cells in the sample and hence was used to increase the detection specificity. 7 (b) Additional allele bands present in tumor samples but not in the corresponding controls were considered as evidence of somatic microsatellite abnormalities. 7, 19, 20, 29 Immunohistochemical Detection of Ki-67, Cell Cycle Regulators, and TERT Sections were mounted on positively charged slides (Superfrost Plus, Fisher Scientific, Fair Lawn, NJ, USA), baked at 601C for 2 h, and processed as described. 22, 24, 30 After routine dewaxing and rehydration, endogenous peroxidase quenching, and antigen heat retrieval, the slides were transferred to a moist chamber. Nonspecific binding was blocked with polyclonal horse serum and sections incubated with monoclonal primary antibodies ( Table 3) . Then sections were serially incubated with biotinylated antimouse antibody, and peroxidase-labeled avidin-biotin complex. The reaction was developed under microscopic control, using 3,3 0 -diaminobenzidine tetrahydrochloride with 0.3% H 2 O 2 as chromogen (Sigma, St Louis, MO, USA), and the sections counterstained with hematoxylin. Both positive (reactive lymph node) and negative (omitting the primary antibody) controls were simultaneously run.
In Situ Hybridization for Telomerase RNA Component (TERC)
Oligonucleotide probes were generated by Primer3 software available free at http://frodo.wi.mit.edu/ cgi-bin/primer3/primer3_www.cgi, using the TERT catalytic domain sequence from NCBI GenBank. Antisense oligonucleotide probes (5 0 -CGTTCCTC TTCCTGCGGCCTG-3 0 complementary to nt 360-381, and 5 0 -CCTCAGTTAGGGTTAGACAAAAAAT GGCCAC-3 0 complementary to nt 31-60, obtained from Operon Europe, Cologne, Germany), sense probe (5 0 -GTGGCCATTTTTTGTCTAACCCTAACTG AG-3 0 from nt 31-60, Operon Europe), and control oligonucleotide (30mer, 5 0 -TTPGGTAACGCCAGGG TTTTCCCAGTCACG-OH-3 0 , provided by Roche Diagnostics GmbH, Mannheim, Germany) were 3 0 -labeled using DIG Oligonucleotide tailing kit (Roche Diagnostics), TdT and a mixture of digoxigeninlabeled dideoxyuridine-triphosphate, and 2 0 -deoxyadenosine 5 0 -triphosphate (dATP), according to the manufacturer's recommendations. The reagents Primer sequences for all these microsatellite markers are available at the Genome database (http://www.gdb.org). Primers were provided by Sigma-Genosys Ltd. Each forward primer was 5 0 -labeled using amidite-labeling chemistry. The fluorescent labels were 6FAM (superscript 'b'), HEX (superscript 'c') and TAMARA (superscript 'a') (ABI3700, filter set D). Primers were re-suspended in TE buffer in three stock mixes (100 mM) that were prediluted in 10 Â primer mix (2 mM of each primer in TE buffer). a TAMARA. b 6FAM. c HE.
were mixed and centrifuged briefly for 2 min, then incubated for 15 min at 371C and subsequently placed on ice. The reaction was stopped by adding 2 ml of 0.2 M EDTA (pH 8.0). The labeled oligonucleotide was not precipitated thereafter.
Paraffin sections (5 mm) were cut onto Superfrost slides (Merck). Sections were deparaffinized, microwaved in pre-warmed 10% citrate buffer (10 min), and pre-hybridized at 421C. Following this, the sections were hybridized with 40 ng/ml of digoxigenin-labeled probe in a pre-hybridization buffer containing dextran sulfate overnight at 421C using a Hybaid Omnislide machine. Following stringency washes to 0.1 Â SCC/50% formamide, sections were stained with anti-digoxigenin-AP Fab fragments. After washing, the sections were developed with nitroblue tetrazolium chloride/bromo-chloro-idolyphosphate (Sigma) chromagen solutions. Stained sections were scored for the intensity of the nuclear mRNA signal. Nuclear and cytoplasmic staining was recorded separately. The slides were counterstained in hematoxylin, coverslipped, and examined under a light microscope. Clearly visualized, finely granular, or tiny dot-like brown stains were considered as positive signals. Far less intense or unequivocal stains that are usually seen in a diffuse manner were regarded as background noise.
Sections were stained on two separate occasions and the results analyzed by two independent observers (EAH and SJD-C). There was o5% variation between sections and observers. Sections of human testicular tissue were used as positive control. The sense probe was used as negative control.
In Situ End Labeling of Fragmented DNA
Extensive DNA fragmentation associated with apoptosis was detected by in situ end labeling as reported. 31, 32 After routine dewaxing and hydration, the sections were incubated in 2 Â standard saline citrate (20 min at 801C) and digested with pronase (500 mg/ml, 25 min, room temperature) in a moist chamber.
DNA fragments were labeled on 5 0 -protruding termini by incubating the sections with the Klenow fragment of Escherichia coli DNA polymerase I (20 U/ml in 50 mmol/l Tris-HCl, pH 7.5, 10 mmol/l MgCl 2 , 1 mmol/l DTT, 250 mg/ml bovine serum albumin, 5 mM each of dATP, dCTP, dGTP, as well as 3.25 mmol/l dTTP, and 1.75 mmol/l 11-digoxigenindUTP), at 371C in a moist chamber. The incorporated digoxigenin-dUMPs were immunoenzymatically detected by using anti-digoxigenin Fab fragments labeled with alkaline phosphatase (7.5 U/ml, in 100 mmol/l Tris-HCl, pH 7.6, 150 mmol/l NaCl, 1% bovine serum albumin) for 4 h at room temperature. The reactions were developed with the mixture of nitroblue tetrazolium-X phosphate in 100 mmol/l Tris-HCl (pH 9.5), 100 mmol/l NaCl, and 50 mmol/l MgCl 2 under microscopic control. Appropriate controls were simultaneously run, including positive (reactive lymph node), negative (same conditions omitting DNA polymerase I), and enzymatic (DNase I digestion before end labeling). The enzymatic controls were used to reliably establish the positivity threshold in each sample. 
Quantification of Positive Nuclei and Statistical Analysis
At least 50 HPFs (7.6 mm 2 ) were screened in each pathological group, beginning with the most cellular area. The number of positive nuclei was expressed per HPF and per 1000 tumor cells, and the average and standard deviation (s.d.) calculated in each pathological condition and patient as described. 23, 24, 32, 33 The positivity threshold was experimentally established at the positive control in each staining batch. Only nuclei with staining features similar to those of their corresponding positive control were considered positive for any marker.
All variables were compared by diagnostic groups and topographic compartments. The normality of quantitative variables was tested by KolmogorovSmirnoff test and then analyzed by Kruskal-Wallis test (more-than-two-group comparisons) or MannWhitney test (two-group comparisons) for nonparametric variables and Student's t-tests for normal variables. The application of non-parametric statistics is more powerful than any centralization analysis based on variables with normal distribution. These non-parametric tests are less intuitive, but more effective in highlighting the statistical differences based on distribution, number of cases in each group, skewness, and variance within and between the groups.
Qualitative variables were compared using chi-square tests and Fisher's exact tests with Yates correction when needed. Differences were considered significant if Po0.05 in two-tailed distributions.
Results
Atypical melanocytic nevi were found in 65 women and 46 men, mean age 36.56 ± 11.94 years, being mainly located in the extremities and trunk (Table 4 ). All nevi met the criteria proposed for atypical melanocytic nevi, 34, 35 and comprised 43 junctional and 80 compound melanocytic nevi, graded atypical melanocytic nevi-mild in 31 (25%), atypical melanocytic nevi-moderate in 61 (50%), and atypical melanocytic nevi-severe in 31 (25%), classified according to the criteria shown in Table 5 . A topographic gradient was observed from junctional to dermal compartments for all markers in all melanocytic lesions, the values being higher in malignant than in benign lesions. The gradient was decreasing for Ki-67, TERT, TERC, TP53, CDKN1A, and pRB1 and increasing for in situ end labeling, CDKN1B, and CDKN2A (Figures 2 and 3) . Although the variability is a factor that can make the interpretation of results more difficult, partially due to the degree of overlapping between groups, it does not make the results invalid per se. Variables like the mitotic figure counting can reveal a high standard deviation in certain malignancies (ie, adrenal cortical carcinomas) and for that reason we cannot conclude that it is not informative (in fact it may represent the single most useful variable for the diagnosis, like in adrenal cortical carcinomas).
Atypical Melanocytic Nevus Grading
There were no statistically significant differences between atypical melanocytic nevi-mild and atypical melanocytic nevi-moderate in any of the variables and compartments except for CDKN1A. The highest CDKN1A expression was observed in the dermal compartment of atypical melanocytic nevi-moderate. Therefore, the statistical analysis was performed by comparing low-grade (mild and moderate) and high-grade (severe) dysplasia. Significant differences were observed in all the studied markers, in one or more compartments except for TERC. Differences were predominantly observed in the junctional compartment, with a minor contribution from the dermal compartment. The low-grade-high-grade transition of atypical (dysplastic) melanocytic lesions revealed an increase of proliferation and telomerase expression and decrease of apoptosis at both junctional and dermal compartments. The junctional compartment showed increasing expression for TP53, CDKN1A, and RB1, along with decreasing expression of CDKN2A and CDKN1B, whereas the dermal compartment revealed increasing expression for TP53, CDKN2A, and RB1, along with decreasing expression of CDKN1A and CDKN1B (Figure 4) . At the expression level, CDKN1B revealed statistically significant differences at both junctional and dermal compartments, and TP53, RB1, and CDKN2A were found to be statistically different at the junctional compartment only. At the microsatellite level, CDK1A was found to be statistically significant at the junctional compartment, while TP53, RB1, and CDKN1B showed statistically significant differences at the dermal compartment.
Microsatellite Profile of Cell Cycle Regulators
Microsatellite abnormalities were significantly more frequent in junctional than in dermal compartments, predominating in melanocytic lesions with high nuclear grade (Figures 3 and 4) . Coexistent microsatellite abnormalities characterized malignant lesions, in particular vertical-growth-phase malignant melanomas, and the lowest incidence of microsatellite abnormalities was present in the dermal compartments of the melanocytic nevus.
The differential comparative pattern was variable, CDKN1B being the marker that discriminated more melanocytic lesions using the microsatellite profile, in particular in the dermal compartments (Figure 3) . Only CDKN1B distinguished low-grade and benign lesions, while among high-grade lesions verticalgrowth-phase malignant melanomas stood as significantly different from both HG-atypical melanocytic nevi and radial-growth-phase malignant melanomas. The distinction between LG-atypical melanocytic nevi and HG-atypical melanocytic nevi was better made in the dermal compartment using TP53, RB1, and CDKN1B, whereas only junctional CDKN1A distinguished LG-atypical melanocytic nevi from HG-atypical melanocytic nevi.
Discussion
High-grade atypical melanocytic nevi accumulate predominantly junctional microsatellite abnormalities of TP53 and cell cycle regulators (CDKN1A and CDKN1B), along with abnormal p53 expression; progression is better assessed by cell cycle regulator expression in dermal compartments and is TP53-independent. Melanocytic nevi and low-grade atypical melanocytic nevi show low incidence of cell cycle regulator abnormalities, and kinetic features that make progression unlikely. As cell topography has not been assessed systematically before in melanocytic lesions, no reference values are available for comparison. For this reason, this discussion mainly focuses on the explanation or biological meaning of the results presented above. Grading and topographic analyses segregate out non-progressive low-grade dysplastic nevi from true malignant melanoma precursors, namely, high-grade atypical melanocytic nevi. These findings support a multistep tumorigenesis and a divergent model of progression as more appropriate than a linear model. A combined topographic and grading stratification of melanocytic lesions offers very useful information on progression: progressive grading parallel to intraepithelial-to-invasive topography of Figure 2 Ki-67 proliferation index (no. of positive nuclei/HPF). High-grade atypical melanocytic nevi showed significantly higher junctional Ki-67 index than low-grade atypical melanocytic nevi, compound melanocytic nevi, and junctional melanocytic nevi (Po0.05 in all groups), whereas there were no significant differences in the Ki-67 index between low-grade atypical melanocytic nevi and compound melanocytic nevi. Ki-67 levels were significantly higher in all radial-growth-phase and vertical-growth-phase malignant melanoma compartments than in the corresponding non-malignant compartments (Po0.05). Some vertical-growth-phase malignant melanomas showed focal Ki-67-positive cell clusters at the advancing tumor edge and heterogeneous staining throughout the lesion. In situ end labeling for apoptosis (no. of positive nuclei/HPF). Low-grade atypical melanocytic nevi and high-grade atypical melanocytic nevi showed significantly higher in situ end labeling indices compared with vertical-growth-phase malignant melanomas in all compartments, but only low-grade atypical melanocytic nevi showed significantly higher in situ end labeling index in the junctional compartment. High-grade atypical melanocytic nevi showed significantly lower in situ end labeling levels than low-grade atypical melanocytic nevi. In comparison with compound melanocytic nevi, significant differences were found between the SD compartments in high-grade atypical melanocytic nevi and compound melanocytic nevi, with the highest values seen in compound melanocytic nevi. TERT (no. of positive nuclei/HPF). All melanocytic groups expressed TERT immunoreactivity with nucleolar (majority of cases) or diffuse nuclear pattern with nucleolar enhancement. The junctional and dermal profiles of high-grade atypical melanocytic nevi were similar but significantly higher than those observed in junctional melanocytic nevi (junctional only), compound melanocytic nevi (junctional and SD), and low-grade atypical melanocytic nevi (junctional and SD), but significantly lower than vertical-growth-phase malignant melanomas in all compartments. The low-grade atypical melanocytic nevi group showed no statistically significant differences when compared with junctional melanocytic nevi and compound melanocytic nevi. . High-grade atypical melanocytic nevi showed significantly higher CDKN1A expression than low-grade atypical melanocytic nevi and compound melanocytic nevi (Po0.5 in both conditions), but not higher than junctional melanocytic nevi. The CDKN1A junctional expression of both low-grade atypical melanocytic nevi and high-grade atypical melanocytic nevi was significantly higher than that of compound melanocytic nevi, but was not significantly different from that of junctional melanocytic nevi. The dermal expression of CDKN1A in low-grade atypical melanocytic nevi and high-grade atypical melanocytic nevi was significantly lower than that in vertical-growth-phase malignant melanomas. In some vertical-growth-phase malignant melanomas, CDKN1A immunoreactivity was restricted to the most peripheral cells in infiltrating dermal nodules. This pattern was not seen in any other melanocytic proliferation. The microsatellite profile was significantly different at the junctional compartment of high-grade atypical melanocytic nevi and vertical-growth-phase malignant melanomas. TP53: Immunoexpression (no. of positive nuclei/HPF). The highest TP53 expression was observed in vertical-growth-phase malignant melanomas (10.0 ± 10.7) and was significantly higher than that in the remaining groups (Po0.01). High-grade atypical melanocytic nevi also revealed significantly higher values than in the other groups (junctional melanocytic nevi, compound melanocytic nevi, and low-grade atypical melanocytic nevi). No TP53 immunoreactivity was observed in dermal compartments except for vertical-growth-phase malignant melanomas. The microsatellite profile was significantly different at the junctional compartment of vertical-growth-phase malignant melanomas and the dermal compartment of high-grade atypical melanocytic nevi and vertical-growth-phase malignant melanomas. CDKN1B: Immunoexpression (no. of positive nuclei/HPF). Low-grade atypical melanocytic nevi and high-grade atypical melanocytic nevi expressed significantly higher CDKN1B levels than vertical-growth-phase malignant melanomas (in all compartments). Low-grade atypical melanocytic nevi showed significant differences compared with compound melanocytic nevi only (in junctional and SD compartments), while high-grade atypical melanocytic nevi showed significantly lower CDKN1B expression than radial-growth-phase malignant melanomas. Junctional and SD compartments of low-grade atypical melanocytic nevi expressed significantly higher CDKN1B levels than the corresponding high-grade atypical melanocytic nevi compartments. Malignant melanoma cells in the vicinity of an ulcerating surface or necrotic foci showed higher expression of CDKN1B; these areas were not included in the final counting procedure. The microsatellite profile was significantly different at the junctional compartment of radial-growth-phase malignant melanomas and vertical-growth-phase malignant melanomas, and the dermal compartment of high-grade atypical melanocytic nevi and vertical-growth-phase malignant melanomas. CDKN2A: Immunoexpression (no. of positive nuclei/HPF). None of the cases of low-grade atypical melanocytic nevi, junctional melanocytic nevi, or compound melanocytic nevi showed complete loss of nuclear CDKN2A at the junction. In dermal compartments, all compound high-grade atypical melanocytic nevi cases expressed nuclear CDKN2A and only one case (2.17%) of lowgrade atypical melanocytic nevi lacked nuclear CDKN2A staining. The mean values of nuclear CDKN2A expression in low-grade atypical melanocytic nevi and high-grade atypical melanocytic nevi were significantly higher than those recorded in radial-and vertical-growthphase malignant melanomas in all compartments. High-grade atypical melanocytic nevi showed statistically significant lower levels of nuclear CDKN2A compared with junctional melanocytic nevi and compound melanocytic nevi (in all compartment). This was also the case when low-grade atypical melanocytic nevi were compared with compound melanocytic nevi in the junctional and SD compartments only. No differences were found between low-grade atypical melanocytic nevi and junctional melanocytic nevi. Both junctional and DD compartments in high-grade atypical melanocytic nevi expressed significantly lower levels of nuclear CDKN2A than low-grade atypical melanocytic nevi. The microsatellite profile was significantly different at the junctional compartment of high-grade atypical melanocytic nevi, radial-and vertical-growth-phase malignant melanomas, and at the dermal compartment of vertical-growthphase malignant melanomas. RB1: Immunoexpression (no. of positive nuclei/HPF). Low-grade atypical melanocytic nevi did not show any significant differences compared with junctional melanocytic nevi (junctional compartment) and compound melanocytic nevi (all compartments). This group expressed lower pRb1 levels than radial-growth-phase malignant melanomas (junctional compartment, Po0.05) and vertical-growth-phase malignant melanomas (all compartments, Po0.001). High-grade atypical melanocytic nevi revealed a statistically significantly higher expression than compound melanocytic nevi and low-grade atypical melanocytic nevi (at the junctional compartment only). However, the expression levels in the SD and DD compartments were significantly lesser than those in verticalgrowth-phase malignant melanomas. The microsatellite profile was significantly different at the junctional and dermal compartments of vertical-growth-phase malignant melanomas. tumor cells would support a linear model. However, differential junctional profiles within individual lesions and the distinction between junctional and dermal components support an independent genetic evolution for high-grade atypical melanocytic nevi, and radial-and vertical-growth-phase melanomas. The atypical melanocytic nevus is assumed to represent a malignant melanoma precursor and a marker of increased malignant melanoma risk, 36, 37 the risk correlating with the degree of dysplasia. 38, 39 The atypical melanocytic nevus grading system is controversial and shows low kappa reproducibility, 40 due to the variable definitions available and the consideration given to moderate dysplasia (either low or high grade). 5, [38] [39] [40] These definitions tried to reflect the lesion biology, but there are no studies assessing cell kinetics, cell cycle regulators, and cell survival by grade and tumor cell topography.
High-grade atypical melanocytic nevi predominantly accumulate junctional microsatellite abnormalities of TP53 and the cell cycle regulators CDKN1A and CDKN1B. High-grade atypical melanocytic nevi revealed the features of established neoplasms (advantageous kinetics, expressed telomerase, and accumulated microsatellite abnormalities, Figure 4 ), 1 but different from both radial-and vertical-growthphase malignant melanoma. 41, 42 The microsatellite patterns do not fit a continuous evolution model from high-grade dysplasia to vertical-growth-phase melanoma: The profiles of malignant melanomas in radial and vertical growth phases (phenotype, kinetics, and CCR microsatellite profile) were different, in that radial-growth-phase malignant melanomas showed microsatellite patterns not fitting the transition between high-grade atypical melanocytic nevi and vertical-growth-phase malignant melanomas. This profile unlikely represents a continuous evolution within a common pathway (linear model of progression); this will explain the difficulty in designing common screening or therapeutic targets for these two different malignancies. 43 It has been normally assumed that tumor progression is a linear process. However, precancerous lesions and early neoplasms (even those with low nuclear grade) can show the genetic and kinetic Kinetic and microsatellites in AMN features of established malignancies (clonal proliferation with accumulation of cooperative genetic abnormalities, and advantageous proliferation/ apoptosis disbalance), along with molecular evidence of progression. 1, 6, 17, 27, 28, 44, 45 This progression would be related to the accumulation of genetic abnormalities and selective segregation of tumor cells with invasive capabilities, which are frequently topographically distributed. 20, 23, 46 A progressive and significant reduction in marker expression from junctional to deep dermal compartments was a general finding mirrored by the microsatellite profile. These findings proved a significant topographic heterogeneity present in all types of melanocytic lesions, even in early lowgrade superficial ones, and features of intraepithelial malignancy for high-grade atypical melanocytic nevi.
Lesions with more atypical features show more molecular abnormalities than low-grade atypical melanocytic nevi, providing diagnostically useful tools. Dermal TP53 alterations characterized the high-grade dysplasias and the vertical-growth-phase melanomas, while the CDKN1B abnormalities defined high-grade dysplastic nevi and melanomas in general. Dermal CDKN2A alterations could be observed in any atypical melanocytic lesion. The cell cycle regulating gene expression and Figure 4 Morphological progression at the junctional compartment of atypical (dysplastic) melanocytic lesions revealed an increase of proliferation and telomerase expression and decrease of apoptosis; the cell cycle regulators showed increasing expression of TP53, CDKN1A, and RB1, along with decreasing expression of CDKN2A and CDKN1B. These changes revealed statistically significant differences for TP53, RB1, CDKN2A, and CDKN1B at the expression level (no. of positive nuclei/HPF) and for CDKN1A at the microsatellite level. Morphological progression at the dermal compartment of atypical (dysplastic) melanocytic lesions revealed an increase of proliferation and telomerase expression and decrease of apoptosis; the cell cycle regulators showed increasing expression of TP53, CDKN2A, and RB1, along with decreasing expression of CDKN1A and CDKN1B. These changes revealed statistically significant differences for CDKN1B at the expression level (no. of positive nuclei/HPF) and for TP53, RB1, and CDKN1B at the microsatellite level.
microsatellite profiles show a junctional-dermal gradient directly correlating with the histological and topographical grading in atypical melanocytic nevi but not in melanomas. Gene expression abnormalities were more frequent than the corresponding microsatellite alterations, suggesting CCR immunoexpression as a sensitive tool for categorization of atypical melanocytic lesions. The most discriminant marker for most categories was CDKN1B; although it has a questioned role as malignant melanoma initiator, it is a useful marker in experimental models. [47] [48] [49] [50] These studies highlight CDKN1B's relevance for characterizing malignant melanomas, but not for malignant melanoma precursors, and do not provide information on the microsatellite profile. CDKN1B microsatellite abnormalities directly correlated with the degree of atypia in intraepithelial lesions and with progression in malignant melanomas. Although the abnormalities are more frequent in the junctional compartment (initiation), the dermal changes are very useful: they reflect tumor progression biologically and the low background level of abnormalities makes the detection more specific technically. Dermal TP53 alterations characterized high-grade atypical melanocytic nevi and vertical-growth-phase malignant melanomas, while CDKN1B abnormalities defined high-grade atypical melanocytic nevi and malignant melanomas; dermal CDKN2A alterations can be observed in any atypical melanocytic lesion, coexisting with other changes in case of invasive malignancy. These changes are meaningful when considering the kinetics of these lesions: the regressive features of low-grade atypical Figure 4 Continued. melanocytic nevi make any progression unlikely (as confirmed by the low incidence of microsatellite abnormalities). Only the superficial dermal expression of CDKN1A differentiated atypical melanocytic nevi-mild from atypical melanocytic nevi-moderate, suggesting that both lesions cannot be reliably distinguished and would favor to group them as low-grade atypical melanocytic nevi. 5, 38 Low-grade atypical melanocytic nevus has a revealed association with histologic regression, suggesting that inflammation regression is unlikely to be secondary to neoplastic progression. 45 The histological regression observed in low-grade atypical melanocytic nevi certainly contributes to the atypical clinical picture and is confirmed by a kinetic profile that suggests a regressive lesion; the potential of neoplastic progression in these atypical melanocytic nevi cannot be predicted on histological grounds only. These findings also have diagnostic implications: pleomorphism, hyperchromatism, and at least another nuclear and architectural abnormality is required for a reliable diagnosis of high-grade atypical melanocytic nevi with regression. 45 In conclusion, early topographic kinetic and microsatellite heterogeneity characterizes atypical melanocytic nevi and suggests an independent evolution for high-grade lesions, which is different from that for invasive malignant melanomas. Progression is better predicted at the dermal compartment and is more likely to follow a divergent rather than a linear model. Conventional melanocytic nevi and low-grade atypical melanocytic nevi show a low incidence of cell cycle regulator abnormalities and kinetic features, which makes progression unlikely.
